PCSK9

PCSK9 Products

  • All (7)
  • PCSK9 Inhibitors (6)
  • PCSK9 Antagonist (1)
  • New PCSK9 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S7976 SBC-115076 SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.
Cancers (Basel), 2024, 16(4)713
Front Cardiovasc Med, 2021, 8:746989
Menopause, 2020, 27(10):1155-1166
A2047 Alirocumab (anti-PCSK9) Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
S8420 R-IMPP R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S0118 SBC-110736 SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116 PF-06446846 hydrochloride PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849 PF-06446846 PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
A2043 Evolocumab (anti-PCSK9) Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
A2047 Alirocumab (anti-PCSK9) Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
A2043 Evolocumab (anti-PCSK9) Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
S8420 R-IMPP R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S0118 SBC-110736 SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116 PF-06446846 hydrochloride PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849 PF-06446846 PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
S7976 SBC-115076 SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.
Cancers (Basel), 2024, 16(4)713
Front Cardiovasc Med, 2021, 8:746989
Menopause, 2020, 27(10):1155-1166

Choose Selective PCSK9 Inhibitors

Tags: PCSK9 inhibitor|PCSK9 agonist|PCSK9 activator|PCSK9 inducer|PCSK9 antagonist|PCSK9 signaling pathway|PCSK9 assay kit